Oncology Drugs Market by Drug Class (Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents), Route of Administration (Injectable, Oral), Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Oncology Drugs Market was valued at USD 210.00 billion in 2024 and is projected to grow to USD 225.54 billion in 2025, with a CAGR of 7.92%, reaching USD 386.41 billion by 2032.
Understanding the Evolving Oncology Drugs Market Dynamics Rooted in Innovation and Patient-Centric Therapeutic Advances
The oncology drugs sector has undergone a profound transformation over the past decade, driven by breakthroughs in molecular biology and a relentless focus on patient outcomes. In this dynamic environment, research and clinical practice converge to accelerate innovations that promise to redefine standards of care. While traditional chemotherapy agents continue to play a vital role in certain cancer types, the advent of immunotherapy, targeted therapies, and personalized treatments has reshaped investment priorities and development pipelines.
Against this backdrop, stakeholders from biopharmaceutical firms to academic institutions must navigate a complex web of regulatory requirements, reimbursement landscapes, and evolving competitive dynamics. This executive summary distills the essential trends, policy shifts, segmentation insights, and regional nuances that are influencing decision-making within the oncology community. By examining factors such as drug class innovations, molecule types, distribution channels, and end-user preferences, the following analysis offers a holistic view of the market’s trajectory.
Emerging Paradigm Shifts in Oncology Therapeutics Driven by Molecular Insights and Treatment Personalization Trends
In recent years, the oncology landscape has experienced several transformative shifts that underscore the transition from one-size-fits-all treatments to precision medicine paradigms. Immunotherapy agents, particularly checkpoint inhibitors and CAR T-cell therapies, have ascended to prominence by harnessing the patient’s own immune system to target malignant cells. At the same time, targeted therapies such as monoclonal antibodies and small molecule inhibitors provide highly specific mechanisms of action, reducing off-target effects and improving response rates.
Concurrently, the integration of biomarkers and genomic profiling has enabled clinicians to tailor therapeutic regimens based on individual tumor characteristics. Digital health platforms and companion diagnostics are increasingly embedded in clinical workflows, facilitating real-time monitoring of treatment efficacy and adverse events. Moreover, collaborative consortia and academic-industry partnerships have accelerated clinical trial enrollment and data sharing, reducing time to market for novel agents. In light of these developments, market participants must remain agile to capitalize on emerging modalities and evolving patient care models.
Analyzing the Far-Reaching Effects of United States Tariff Policies on Oncology Drug Access Development and Global Collaboration in 2025
The introduction of new United States tariff policies in 2025 has catalyzed a reassessment of global supply chain strategies for oncology drug development and distribution. With certain active pharmaceutical ingredients and biologic components facing increased import duties, companies are evaluating domestic manufacturing partnerships and vertical integration to mitigate cost pressures. This strategic pivot not only influences operational budgets but also impacts negotiations with contract development and manufacturing organizations.
In addition, heightened tariffs have prompted multinational corporations to revisit pricing models and market launch sequences. As a result, stakeholders must balance the need to preserve profit margins with the imperative of ensuring patient access. Collaborations between industry and regulatory bodies have become critical in identifying exemptions for life-saving therapies. Consequently, agility in sourcing materials and proactive engagement with policymakers will be defining features of successful oncology portfolios in the evolving tariff landscape.
Deep Dive into Oncology Drugs Market Segmentation Revealing Trends Across Drug Classes Administration Routes Molecule Types Indications and End Users
A nuanced examination of market segmentation reveals distinct growth drivers and competitive dynamics. Within drug classes, chemotherapy agents remain essential for various indications, yet hormonal therapy agents and immunotherapy agents such as CAR T-cell therapies and checkpoint inhibitors are claiming greater share of research focus. Checkpoint inhibitors are further differentiated into CTLA-4 inhibitors and PD-1/PD-L1 inhibitors, each with unique safety profiles and efficacy benchmarks. Targeted therapy agents, encompassing monoclonal antibodies-both chimeric and humanized-and small molecule inhibitors including cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors, deliver precision at a molecular level.
Routes of administration also influence adoption patterns, as injectable therapies administered intravenously, subcutaneously, or intramuscularly cater to hospital settings, while oral formulations empower outpatient care. From a molecule type perspective, the biologics segment extends beyond monoclonal antibodies to encompass vaccines, while small molecules retain advantages in chemical stability and cost. Clinical indications drive demand for specialized treatment regimens across blood cancers-such as acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma-alongside solid tumors including breast, colorectal, lung, and prostate cancers. Finally, end users span hospitals, research institutes, and specialty clinics, with distribution channels ranging from hospital pharmacies to online and retail pharmacies, underscoring the importance of tailored supply chain strategies.
Comprehensive Regional Analysis Highlighting Oncology Drug Market Trends across Americas Europe Middle East Africa and Asia Pacific Dynamics
Regional disparities shape both clinical practice and market potential in oncology therapeutics. In the Americas, a mature regulatory framework facilitates rapid product approvals, while established reimbursement pathways support broad patient access. Innovation hubs in North America foster collaborations that accelerate clinical trial execution and real-world evidence generation. Meanwhile, Central and South American markets are witnessing incremental growth fueled by public-private partnerships aimed at enhancing oncology care infrastructure.
Across Europe, the Middle East, and Africa, the interplay between national health technology assessments and variable reimbursement models creates a mosaic of market entry strategies. Some governments prioritize cost-containment, spurring interest in biosimilars and generics, whereas others incentivize breakthrough therapies through expedited pathways. In the Asia-Pacific region, burgeoning investments in local manufacturing and regulatory harmonization are increasing availability of both biologics and small molecules, as emerging economies expand access to next-generation oncology treatments. These regional dynamics demand tailored market approaches that account for policy environments, healthcare spending trends, and patient demographics.
Strategic Corporate Profiles Spotlighting Leading Oncology Drug Developers Innovators and Collaborators Shaping Industry Progress
Leading biopharmaceutical companies are advancing diversified oncology portfolios that span from early-stage discovery to late-phase clinical development. Several organizations are leveraging strategic acquisitions to bolster pipelines in immuno-oncology and targeted therapies, while others are establishing co-development agreements to share risk and accelerate time to market. Key players are also deploying companion diagnostic platforms to enhance patient selection and improve clinical outcomes.
Innovation is further stimulated by collaborations with academic centers and technology firms developing artificial intelligence-driven drug discovery tools. Meanwhile, mid-size biotech enterprises are carving niches by focusing on orphan indications and novel mechanisms of action. Competitive differentiation increasingly hinges on the ability to demonstrate value through pharmacoeconomic analyses and real-world evidence, positioning certain companies as preferred partners for payers and healthcare providers.
Proactive Business and Research Recommendations Empowering Industry Leaders to Navigate Oncology Drug Challenges and Leverage Growth Opportunities
To capitalize on the evolving oncology landscape, industry leaders should prioritize investments in biomarker-driven development programs that align with precision medicine objectives. Strengthening supply chain resilience through diversified sourcing and near-shoring strategies will mitigate tariff-related disruptions while ensuring uninterrupted access for patients. Enhanced collaboration with regulatory agencies can secure accelerated approvals and obtain designation for breakthrough therapies, further reducing time to market.
Embracing digital health tools for remote monitoring and patient engagement will improve adherence and real-world data collection, informing post-launch optimization efforts. Companies should also explore value-based pricing models that link outcomes to reimbursement, thereby demonstrating cost-effectiveness to payers. Finally, forging partnerships with academic institutions and technology startups can unlock new modalities and streamline clinical operations, sustaining innovation momentum in the competitive oncology arena.
Rigorous Multi-Source Research Approach Combining Qualitative and Quantitative Analyses to Ensure Robust Oncology Drug Market Insights
This report’s findings derive from a robust research methodology that integrates primary and secondary data sources. Expert interviews with oncologists, regulatory officials, and supply chain specialists provided qualitative insights into clinical and commercial challenges. Complementing these perspectives, secondary research encompassed peer-reviewed journals, clinical trial registries, regulatory filings, and company disclosures. Comprehensive data triangulation ensured consistency and validity across multiple sources.
Segmentation frameworks were constructed to map market dynamics across drug classes, administration routes, molecule types, indications, end-user categories, and distribution channels. Regional analyses incorporated healthcare expenditure statistics, reimbursement policies, and demographic data. Finally, in-house analytical models were applied to assess the impact of regulatory changes, tariff adjustments, and emerging therapeutic trends, delivering a holistic and actionable perspective.
Synthesizing Critical Findings to Chart the Future of Oncology Drug Development Regulation and Market Evolution
In summary, the oncology drugs market is characterized by a shift toward precision medicine, driven by immuno-oncology modalities, targeted therapies, and integrated diagnostics. Tariff policy changes are reshaping supply chains and cost structures, underscoring the need for strategic sourcing and regulatory engagement. Segmentation analysis highlights the diverse needs across drug classes, administration routes, molecule types, clinical indications, end users, and distribution channels, each influencing market trajectories.
Regional variations further reinforce the importance of tailored strategies that address local regulatory frameworks, reimbursement models, and infrastructure capabilities. Corporate innovation and strategic partnerships remain central to competitive differentiation, while value-based approaches and digital health integration will define future success. As the sector continues to evolve, stakeholders must embrace agility, collaboration, and data-driven decision making to deliver impactful oncology treatments and optimize patient outcomes.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Drug Class
Chemotherapy Agents
Alkylating Agents
Antimetabolites
Hormonal Therapy Agents
Immunotherapy Agents
CAR T-Cell Therapy
Checkpoint Inhibitors
CTLA-4 Inhibitors
PD-1/PD-L1 Inhibitors
Targeted Therapy Agents
Monoclonal Antibodies
Chimeric
Humanized
Small Molecule Inhibitors
Cyclin-Dependent Kinase Inhibitors
Tyrosine Kinase Inhibitors
Route of Administration
Injectable
Intramuscular
Intravenous
Subcutaneous
Oral
Molecule Type
Biologics
Monoclonal Antibodies
Vaccines
Small Molecules
Indication
Blood Cancer
Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
End User
Hospitals
Research Institutes
Specialty Clinics
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
AbbVie Inc.
Agenus Inc.
Amgen Inc.
Après-demain SA
Aspen Pharmacare Holdings Limited
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
BeiGene, Inc.
Bristol-Myers Squibb Company
C.H. Boehringer Sohn AG & Co. KG
Cipla Limited
Eli Lilly and Company
GSK plc
Johnson & Johnson Services, Inc.
Merck KGaA
Pfizer Inc.
Puma Biotechnology, Inc.
Roche Holding AG
Shorla Oncology
Sun Pharmaceutical Industries Ltd
Sutro Biopharma, Inc.
Takeda Pharmaceutical Company Limited
Viatris Inc.
Please Note: PDF & Excel + Online Access - 1 Year
Understanding the Evolving Oncology Drugs Market Dynamics Rooted in Innovation and Patient-Centric Therapeutic Advances
The oncology drugs sector has undergone a profound transformation over the past decade, driven by breakthroughs in molecular biology and a relentless focus on patient outcomes. In this dynamic environment, research and clinical practice converge to accelerate innovations that promise to redefine standards of care. While traditional chemotherapy agents continue to play a vital role in certain cancer types, the advent of immunotherapy, targeted therapies, and personalized treatments has reshaped investment priorities and development pipelines.
Against this backdrop, stakeholders from biopharmaceutical firms to academic institutions must navigate a complex web of regulatory requirements, reimbursement landscapes, and evolving competitive dynamics. This executive summary distills the essential trends, policy shifts, segmentation insights, and regional nuances that are influencing decision-making within the oncology community. By examining factors such as drug class innovations, molecule types, distribution channels, and end-user preferences, the following analysis offers a holistic view of the market’s trajectory.
Emerging Paradigm Shifts in Oncology Therapeutics Driven by Molecular Insights and Treatment Personalization Trends
In recent years, the oncology landscape has experienced several transformative shifts that underscore the transition from one-size-fits-all treatments to precision medicine paradigms. Immunotherapy agents, particularly checkpoint inhibitors and CAR T-cell therapies, have ascended to prominence by harnessing the patient’s own immune system to target malignant cells. At the same time, targeted therapies such as monoclonal antibodies and small molecule inhibitors provide highly specific mechanisms of action, reducing off-target effects and improving response rates.
Concurrently, the integration of biomarkers and genomic profiling has enabled clinicians to tailor therapeutic regimens based on individual tumor characteristics. Digital health platforms and companion diagnostics are increasingly embedded in clinical workflows, facilitating real-time monitoring of treatment efficacy and adverse events. Moreover, collaborative consortia and academic-industry partnerships have accelerated clinical trial enrollment and data sharing, reducing time to market for novel agents. In light of these developments, market participants must remain agile to capitalize on emerging modalities and evolving patient care models.
Analyzing the Far-Reaching Effects of United States Tariff Policies on Oncology Drug Access Development and Global Collaboration in 2025
The introduction of new United States tariff policies in 2025 has catalyzed a reassessment of global supply chain strategies for oncology drug development and distribution. With certain active pharmaceutical ingredients and biologic components facing increased import duties, companies are evaluating domestic manufacturing partnerships and vertical integration to mitigate cost pressures. This strategic pivot not only influences operational budgets but also impacts negotiations with contract development and manufacturing organizations.
In addition, heightened tariffs have prompted multinational corporations to revisit pricing models and market launch sequences. As a result, stakeholders must balance the need to preserve profit margins with the imperative of ensuring patient access. Collaborations between industry and regulatory bodies have become critical in identifying exemptions for life-saving therapies. Consequently, agility in sourcing materials and proactive engagement with policymakers will be defining features of successful oncology portfolios in the evolving tariff landscape.
Deep Dive into Oncology Drugs Market Segmentation Revealing Trends Across Drug Classes Administration Routes Molecule Types Indications and End Users
A nuanced examination of market segmentation reveals distinct growth drivers and competitive dynamics. Within drug classes, chemotherapy agents remain essential for various indications, yet hormonal therapy agents and immunotherapy agents such as CAR T-cell therapies and checkpoint inhibitors are claiming greater share of research focus. Checkpoint inhibitors are further differentiated into CTLA-4 inhibitors and PD-1/PD-L1 inhibitors, each with unique safety profiles and efficacy benchmarks. Targeted therapy agents, encompassing monoclonal antibodies-both chimeric and humanized-and small molecule inhibitors including cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors, deliver precision at a molecular level.
Routes of administration also influence adoption patterns, as injectable therapies administered intravenously, subcutaneously, or intramuscularly cater to hospital settings, while oral formulations empower outpatient care. From a molecule type perspective, the biologics segment extends beyond monoclonal antibodies to encompass vaccines, while small molecules retain advantages in chemical stability and cost. Clinical indications drive demand for specialized treatment regimens across blood cancers-such as acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma-alongside solid tumors including breast, colorectal, lung, and prostate cancers. Finally, end users span hospitals, research institutes, and specialty clinics, with distribution channels ranging from hospital pharmacies to online and retail pharmacies, underscoring the importance of tailored supply chain strategies.
Comprehensive Regional Analysis Highlighting Oncology Drug Market Trends across Americas Europe Middle East Africa and Asia Pacific Dynamics
Regional disparities shape both clinical practice and market potential in oncology therapeutics. In the Americas, a mature regulatory framework facilitates rapid product approvals, while established reimbursement pathways support broad patient access. Innovation hubs in North America foster collaborations that accelerate clinical trial execution and real-world evidence generation. Meanwhile, Central and South American markets are witnessing incremental growth fueled by public-private partnerships aimed at enhancing oncology care infrastructure.
Across Europe, the Middle East, and Africa, the interplay between national health technology assessments and variable reimbursement models creates a mosaic of market entry strategies. Some governments prioritize cost-containment, spurring interest in biosimilars and generics, whereas others incentivize breakthrough therapies through expedited pathways. In the Asia-Pacific region, burgeoning investments in local manufacturing and regulatory harmonization are increasing availability of both biologics and small molecules, as emerging economies expand access to next-generation oncology treatments. These regional dynamics demand tailored market approaches that account for policy environments, healthcare spending trends, and patient demographics.
Strategic Corporate Profiles Spotlighting Leading Oncology Drug Developers Innovators and Collaborators Shaping Industry Progress
Leading biopharmaceutical companies are advancing diversified oncology portfolios that span from early-stage discovery to late-phase clinical development. Several organizations are leveraging strategic acquisitions to bolster pipelines in immuno-oncology and targeted therapies, while others are establishing co-development agreements to share risk and accelerate time to market. Key players are also deploying companion diagnostic platforms to enhance patient selection and improve clinical outcomes.
Innovation is further stimulated by collaborations with academic centers and technology firms developing artificial intelligence-driven drug discovery tools. Meanwhile, mid-size biotech enterprises are carving niches by focusing on orphan indications and novel mechanisms of action. Competitive differentiation increasingly hinges on the ability to demonstrate value through pharmacoeconomic analyses and real-world evidence, positioning certain companies as preferred partners for payers and healthcare providers.
Proactive Business and Research Recommendations Empowering Industry Leaders to Navigate Oncology Drug Challenges and Leverage Growth Opportunities
To capitalize on the evolving oncology landscape, industry leaders should prioritize investments in biomarker-driven development programs that align with precision medicine objectives. Strengthening supply chain resilience through diversified sourcing and near-shoring strategies will mitigate tariff-related disruptions while ensuring uninterrupted access for patients. Enhanced collaboration with regulatory agencies can secure accelerated approvals and obtain designation for breakthrough therapies, further reducing time to market.
Embracing digital health tools for remote monitoring and patient engagement will improve adherence and real-world data collection, informing post-launch optimization efforts. Companies should also explore value-based pricing models that link outcomes to reimbursement, thereby demonstrating cost-effectiveness to payers. Finally, forging partnerships with academic institutions and technology startups can unlock new modalities and streamline clinical operations, sustaining innovation momentum in the competitive oncology arena.
Rigorous Multi-Source Research Approach Combining Qualitative and Quantitative Analyses to Ensure Robust Oncology Drug Market Insights
This report’s findings derive from a robust research methodology that integrates primary and secondary data sources. Expert interviews with oncologists, regulatory officials, and supply chain specialists provided qualitative insights into clinical and commercial challenges. Complementing these perspectives, secondary research encompassed peer-reviewed journals, clinical trial registries, regulatory filings, and company disclosures. Comprehensive data triangulation ensured consistency and validity across multiple sources.
Segmentation frameworks were constructed to map market dynamics across drug classes, administration routes, molecule types, indications, end-user categories, and distribution channels. Regional analyses incorporated healthcare expenditure statistics, reimbursement policies, and demographic data. Finally, in-house analytical models were applied to assess the impact of regulatory changes, tariff adjustments, and emerging therapeutic trends, delivering a holistic and actionable perspective.
Synthesizing Critical Findings to Chart the Future of Oncology Drug Development Regulation and Market Evolution
In summary, the oncology drugs market is characterized by a shift toward precision medicine, driven by immuno-oncology modalities, targeted therapies, and integrated diagnostics. Tariff policy changes are reshaping supply chains and cost structures, underscoring the need for strategic sourcing and regulatory engagement. Segmentation analysis highlights the diverse needs across drug classes, administration routes, molecule types, clinical indications, end users, and distribution channels, each influencing market trajectories.
Regional variations further reinforce the importance of tailored strategies that address local regulatory frameworks, reimbursement models, and infrastructure capabilities. Corporate innovation and strategic partnerships remain central to competitive differentiation, while value-based approaches and digital health integration will define future success. As the sector continues to evolve, stakeholders must embrace agility, collaboration, and data-driven decision making to deliver impactful oncology treatments and optimize patient outcomes.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Drug Class
Chemotherapy Agents
Alkylating Agents
Antimetabolites
Hormonal Therapy Agents
Immunotherapy Agents
CAR T-Cell Therapy
Checkpoint Inhibitors
CTLA-4 Inhibitors
PD-1/PD-L1 Inhibitors
Targeted Therapy Agents
Monoclonal Antibodies
Chimeric
Humanized
Small Molecule Inhibitors
Cyclin-Dependent Kinase Inhibitors
Tyrosine Kinase Inhibitors
Route of Administration
Injectable
Intramuscular
Intravenous
Subcutaneous
Oral
Molecule Type
Biologics
Monoclonal Antibodies
Vaccines
Small Molecules
Indication
Blood Cancer
Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
End User
Hospitals
Research Institutes
Specialty Clinics
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
AbbVie Inc.
Agenus Inc.
Amgen Inc.
Après-demain SA
Aspen Pharmacare Holdings Limited
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
BeiGene, Inc.
Bristol-Myers Squibb Company
C.H. Boehringer Sohn AG & Co. KG
Cipla Limited
Eli Lilly and Company
GSK plc
Johnson & Johnson Services, Inc.
Merck KGaA
Pfizer Inc.
Puma Biotechnology, Inc.
Roche Holding AG
Shorla Oncology
Sun Pharmaceutical Industries Ltd
Sutro Biopharma, Inc.
Takeda Pharmaceutical Company Limited
Viatris Inc.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid adoption of personalized neoantigen vaccine platforms targeting tumor-specific mutations in solid cancers
- 5.2. Growing integration of ultra-sensitive liquid biopsy assays for minimal residual disease monitoring in hematologic malignancies
- 5.3. Expansion of CD19-targeted CAR T cell therapies into earlier lines of diffuse large B cell lymphoma treatment protocols
- 5.4. Emergence of next generation KRAS G12C and G12D inhibitors demonstrating durable responses across lung and colorectal cancers
- 5.5. Increasing partnerships between pharmaceutical companies and diagnostic developers for PD-L1 companion diagnostic co-development programs
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Oncology Drugs Market, by Drug Class
- 8.1. Chemotherapy Agents
- 8.1.1. Alkylating Agents
- 8.1.2. Antimetabolites
- 8.2. Hormonal Therapy Agents
- 8.3. Immunotherapy Agents
- 8.3.1. CAR T-Cell Therapy
- 8.3.2. Checkpoint Inhibitors
- 8.3.2.1. CTLA-4 Inhibitors
- 8.3.2.2. PD-1/PD-L1 Inhibitors
- 8.4. Targeted Therapy Agents
- 8.4.1. Monoclonal Antibodies
- 8.4.1.1. Chimeric
- 8.4.1.2. Humanized
- 8.4.2. Small Molecule Inhibitors
- 8.4.2.1. Cyclin-Dependent Kinase Inhibitors
- 8.4.2.2. Tyrosine Kinase Inhibitors
- 9. Oncology Drugs Market, by Route of Administration
- 9.1. Injectable
- 9.1.1. Intramuscular
- 9.1.2. Intravenous
- 9.1.3. Subcutaneous
- 9.2. Oral
- 10. Oncology Drugs Market, by Molecule Type
- 10.1. Biologics
- 10.1.1. Monoclonal Antibodies
- 10.1.2. Vaccines
- 10.2. Small Molecules
- 11. Oncology Drugs Market, by Indication
- 11.1. Blood Cancer
- 11.1.1. Leukemia
- 11.1.1.1. Acute Myeloid Leukemia
- 11.1.1.2. Chronic Lymphocytic Leukemia
- 11.1.2. Lymphoma
- 11.1.2.1. Hodgkin Lymphoma
- 11.1.2.2. Non-Hodgkin Lymphoma
- 11.2. Breast Cancer
- 11.3. Colorectal Cancer
- 11.4. Lung Cancer
- 11.5. Prostate Cancer
- 12. Oncology Drugs Market, by End User
- 12.1. Hospitals
- 12.2. Research Institutes
- 12.3. Specialty Clinics
- 13. Oncology Drugs Market, by Distribution Channel
- 13.1. Hospital Pharmacies
- 13.2. Online Pharmacies
- 13.3. Retail Pharmacies
- 14. Oncology Drugs Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Oncology Drugs Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Oncology Drugs Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. AbbVie Inc.
- 17.3.2. Agenus Inc.
- 17.3.3. Amgen Inc.
- 17.3.4. Après-demain SA
- 17.3.5. Aspen Pharmacare Holdings Limited
- 17.3.6. Astellas Pharma Inc.
- 17.3.7. AstraZeneca PLC
- 17.3.8. Bayer AG
- 17.3.9. BeiGene, Inc.
- 17.3.10. Bristol-Myers Squibb Company
- 17.3.11. C.H. Boehringer Sohn AG & Co. KG
- 17.3.12. Cipla Limited
- 17.3.13. Eli Lilly and Company
- 17.3.14. GSK plc
- 17.3.15. Johnson & Johnson Services, Inc.
- 17.3.16. Merck KGaA
- 17.3.17. Pfizer Inc.
- 17.3.18. Puma Biotechnology, Inc.
- 17.3.19. Roche Holding AG
- 17.3.20. Shorla Oncology
- 17.3.21. Sun Pharmaceutical Industries Ltd
- 17.3.22. Sutro Biopharma, Inc.
- 17.3.23. Takeda Pharmaceutical Company Limited
- 17.3.24. Viatris Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
